• Ahmet Yilmaz, Selin Hanlioğlu, Gökhan Demiral, and Oğuzhan Karatepe.
• Medipol University, Faculty of Medicine, Department of General Surgery - İstanbul, Turkey.
• Rev Assoc Med Bras (1992). 2023 Jan 1; 69 (12): e20230571e20230571.

ObjectiveIntragastric balloon placement is an effective method for weight reduction. The aim of this study was to evaluate the efficacy of combining liraglutide with intragastric balloon.MethodsInitially, demographic data of patients such as age, gender, comorbid diseases, adverse events, initial weight, height, body mass index, percent body fat, and waist-hip ratio were collected. Weight, body mass index, percent body fat, and waist-hip ratio were measured in the second, third, fourth, fifth, and sixth months. Then, intragastric balloon was removed and liraglutide was stopped.ResultsA total of 50 patients were included in the study, of whom 28 (56%) were in Group A (intragastric balloon) and 22 (44%) were in Group B (plus liraglutide). Weight change at the time of balloon removal was higher in Group B [median weight change 13.8 (7.8 min to 16.8 max) versus 7.9 (4.8 min to 11.8 max); p<0.01]. When the weight, percent body fat, body mass index, and waist-hip ratio changes were compared according to gender, no significant difference was observed in the groups. Comorbid diseases were hypertension in 7 patients (4 in Group A and 3 in Group B) and diabetes in 9 patients (5 in Group A and 4 in Group B). No statistical significance was found.ConclusionLiraglutide has benefits in terms of weight, percent body fat, and body mass index reduction when administered with intragastric balloon.

12 keywords...

hide…